Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $160.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 8.34% to $160.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $160.6 million through Dec 2025, down 8.34% year-over-year, with the annual reading at $160.6 million for FY2025, 8.34% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $160.6 million at Centessa Pharmaceuticals, up from $146.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $175.2 million in Q4 2024, with the low at $101.0 million in Q2 2022.
  • Average Total Non-Current Liabilities over 4 years is $126.8 million, with a median of $113.0 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities soared 41.34% in 2024, then dropped 8.34% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $108.1 million in 2022, then increased by 14.64% to $124.0 million in 2023, then soared by 41.34% to $175.2 million in 2024, then fell by 8.34% to $160.6 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $160.6 million, $146.7 million, and $147.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.